Primary orbital pleomorphic liposarcoma in a child: A case report

Trakanta Wannapanich, Paitoon Pratipanawat

Faculty of Medicine, Khon Kaen University, Thailand

A B S T R A C T

Keywords:
Primary orbital liposarcoma
Pleomorphic liposarcoma
Pediatric sarcoma

Purpose: To report a rare case of primary orbital pleomorphic liposarcoma and present a relevant literature review.

Observations: An 11-year-old boy presented with an enlarging, painless lower right eyelid mass that was noted 4 months ago. Imaging revealed a 3.2 × 2.1 × 3.7-cm-sized well-circumscribed lobulated mass. Biopsy revealed a pleomorphic spindle cell neoplasm that was consistent with a pleomorphic liposarcoma. A systemic evaluation found no evidence of distant metastasis. Despite four chemotherapy cycles, the mass size increased at follow-up. Total orbital exenteration was performed 1 year after confirming a diagnosis of pleomorphic liposarcoma. At the 6-month follow-up, the patient was alive with no signs of recurrence.

Conclusions: Pediatric pleomorphic liposarcoma is a very rare entity. Its definite diagnosis relies on histopathological results. In the absence of systemic metastasis, total orbital exenteration is the optimal approach for local control.

1. Introduction

Liposarcoma is a common soft tissue tumor in adults but a very rare entity in children, accounting for <3% of all pediatric sarcomas.1 According to the 2020 World Health Organization soft tissue and bone tumors classification, malignant adipocytic tumors are histologically classified as well-differentiated, myxoid, pleomorphic, myxoid pleomorphic, and dedifferentiated liposarcomas.2 Well-differentiated liposarcoma is the most common subtype in adults,3 whereas the myxoid subtype is the most common in children.4

Pleomorphic liposarcoma is the rarest subtype (5% of all liposarcomas).2 The most common primary sites are the extremities, followed by the internal trunk, and the prognosis is generally unfavorable, with high rates of local recurrences. More than one-third of patients who undergo complete resection develop distant metastasis.5

The orbit is an extremely rare primary site for liposarcomas and even rarer for pleomorphic subtypes. Only seven case reports of primary orbital pleomorphic liposarcoma have been found in the literature since 1990, and only two of them were in patients aged <20 years.6–12 This report presents a rare case of a primary orbital pleomorphic liposarcoma in an 11-year-old boy.

2. Case report

An 11-year-old Asian boy with an enlarging lower right eyelid mass was referred to our hospital for further evaluation and complete tumor removal. The child had homozygous hemoglobin E disease, with no anemic symptoms, as an underlying disease. He denied any significant past ocular history or family history of malignancy at a young age. Four months ago, he first noticed this painless mass of approximately 1 cm. Two months after the mass had developed, the child underwent contrast-enhanced orbital magnetic resonance imaging (MRI), which revealed a 3.2 × 2.1 × 3.7-cm-sized well-circumscribed lobulated mass on the lower right eyelid, abutting on the right inferior rectus muscle and causing superior right eye globe displacement.

On physical examination, his best-corrected visual acuity was 2/60 OD and 6/12 OS, with normal pupil reaction. External examination showed a 5-cm-painless, firm lower right eyelid mass. The mass caused superior globe displacement, complete ptosis, marked conjunctival chemosis, and limited extraocular muscle movement, with the greatest restriction on the inferior directions (Fig. 1A). The left eye examination was unremarkable, with full motility in all directions. Clinical differential diagnosis included orbital tumor not otherwise specified and vascular malformations, including venous lymphatic and cavernous venous malformations. Follow-up MRI after 1 month revealed an increase in the solid mass size to approximately 4.9 × 3.9 × 3.2 cm, with...
posterior extension to the anterior right orbit extraconal space (Fig. 2). Incisional biopsy revealed a pleomorphic spindle cell neoplasm with hyperchromatic nuclei, high-N/C ratio, coarse chromatin and some cells showed lipoblast-like features. The results were consistent with a pleomorphic liposarcoma. A rare mitosis was noted (0–9 mitoses per 10 high-power field). Immunohistochemical examinations were negative for AE1/AE3, EMA, S100, and HMB45. The patient was referred to the pediatric oncology unit. Further evaluations including brain imaging, chest computed tomography, and bone scan found no evidence of distant metastases. Neoadjuvant chemotherapy (protocol ThaiPOG-NRMS-1801 for non-rhabdomyosarcoma, Arm D), including ifosfamide and doxorubicin, was administered as four cycles in total (3 weeks apart). The mass slightly increased in size at the follow-up examination, and a trace relative afferent pupillary defect of the right eye was noted (Fig. 1B). Orbital computed tomography revealed that the heterogenous enhancing mass increased in size, measuring approximately 5.0 × 6.0 × 5.0 cm. The tumor caused pressure that pushed the right eye globe superiorly and the superior maxillary sinus inferiorly. The extraconal and intraconal fats were also involved in the tumor (Fig. 3). Total exenteration of the right orbit was performed 13 weeks after chemotherapy was initiated. The socket was left to granulate. Pathological results confirmed the pleomorphic liposarcoma diagnosis, and the tumor measured approximately 5.5 × 5.0 × 4.0 cm (Supplementary Figs. S1 and S2). All margins except the lateral ones were uninvolved with the tumor (anterior, posterior, and inferior <1 mm, superior 20 mm, medial 2 mm). The patient received postoperative adjuvant chemotherapy, following the same protocol as in the preoperative period. Intensity-modulated radiation therapy (IMRT) was administered with 200 cGy per fraction for 33 fractions (a total dose of 6600 cGy) during a 6-week period to counter possible microscopic residual tumor tissues. No significant change in the patient’s anemic profile was noted after treatment completion. No signs of recurrence were noted at the 6-month post-exenteration follow-up.

3. Discussion

Liposarcoma of the head and neck region is a rare entity. The pleomorphic subtype is a high-grade undifferentiated sarcoma with a variable number of pleomorphic lipoblasts and has the most aggressive course, with a 1-year survival rate of approximately 45%. This tumor was reported to rarely metastasize but could be locally invasive. The most common metastatic site was the lungs, followed by the liver and skeleton. We found only seven case reports on primary orbital pleomorphic liposarcomas after reviewing the literature since 1990 (Table 1).

The tumor was surgically resected in all of the cases, either via local resection or exenteration. Two patients died, whereas the others showed no sign of recurrence or were lost to follow-up. Liposarcoma is extremely uncommon in children. The most common primary site in adults is the extremities. Madge et al. reported on a 19-year-old Caucasian man with primary orbital pleomorphic liposarcoma. The patient was treated with combined chemotherapy and local resection and underwent exenteration 5 years after the initial presentation. As multiple recurrences were found, the patient was treated with combined chemotherapy, radiotherapy, and multiple tumor resections before the disease was controlled. Rudzinski et al. reported on a primary orbital pleomorphic liposarcoma in an 8-year-old boy who presented with a swollen left eye for 3 months. Initially, there was no evidence of metastasis; however, he later developed metastatic disease. Despite aggressive treatments, he died 2 years after the initial symptoms.

The treatment option for liposarcomas is primarily surgical resection, and it is generally recommended to excise at least 2 cm of negative surgical margins in cases of soft tissue sarcomas. However, the possibility of achieving this wide margin is more difficult in the head and neck region than in the rest of the body. Only 2–5% of head and neck liposarcoma cases were treated with adjuvant radiotherapy, which is a rate lower than that observed for other body regions. This was explained by its inconclusive efficacy and overall survival benefits. In our case, postoperative radiotherapy was performed to improve local tumor control because there was a positive surgical margin. Chemotherapy might provide an additional benefit for localized resectable soft tissue sarcomas, as was demonstrated in a meta-analysis. The combination of doxorubicin and ifosfamide is the preferred treatment; however, this treatment must be weighed against associated toxicities. Our patient tolerated the systemic chemotherapy well, with no documented severe adverse events.

4. Conclusions

We described the clinical features of an 11-year-old boy with primary orbital pleomorphic liposarcoma, a rare entity. Diagnosis primarily depended on histopathological findings obtained via biopsy. In the absence of systemic metastasis, total exenteration of the orbit with adequate surgical margin seemed to be the best treatment option. Adjunctive chemotherapy or radiotherapy might improve local control, although the decision should be weighed against the risk. Clinicians should consider liposarcoma as a differential diagnosis of orbital masses in children.
Table 1

| Author             | Age/ Sex | Symptoms/Duration | Location                                      | Size | Treatment                                           | Follow-up             |
|--------------------|----------|-------------------|-----------------------------------------------|------|----------------------------------------------------|-----------------------|
| McNab and Moseley  | 52/M     | Blurred vision/7 months | Intraconal, abutting the medial rectus and upper surface of the optic nerve | 2 cm | Exenteration                                      | 12 months NSR        |
| Cai et al.         | 51/M     | Diplopia, proptosis/several months | Retrobulbar and inferior involving lower eyelid | 4 cm | Exenteration                                      | 65 months NSR        |
| Monteiro           | 75/M     | Diplopia, proptosis/3 months | Medial rectus muscle                           | NA   | Exenteration, post-op RT                           | 6 years NSR           |
| Madge et al.       | 19/M     | Proptosis/5 months  | Extraconal, superomedial quadrant of the orbit | NA   | Local resection, CMT, exenteration, post-op RT      | 9.5 years NSR         |
| Rudzinski et al.   | 8/M      | Swollen eye/3 months | Extraconal, anterior to superior rectus muscle insertion | NA   | Local resection, CMT, post-op RT                    | Death after 2 years due to metastasis |
| Doyle et al.       | 62/F     | Diplopia, proptosis/5 months | Retrobulbar, invading the paranasal sinus      | 5 cm | Local resection                                    | Lost to follow-up after 2 years |
| Jang et al.        | 59/M     | Proptosis/NA       | Retrobulbar                                   | NA   | Exenteration, post-op RT                           | Death after 1 year due to metastasis |

CMT, chemotherapy; F, female; M, male; NA, information not available; NSR, no sign of recurrence; RT, radiotherapy.
Author statement

Trakanta Wannapanich: Conceptualization, Methodology, Validation, Writing - Original Draft, Writing - Review & Editing, Visualization.

Paitoon Pratipanawat: Validation, Writing - Review & Editing, Supervision, Project administration, Funding acquisition.

Patient consent

Both patient and patient’s legal guardian consented to publication of the case in writing. The patient and his parents have given their permission to publish their clinical data and images.

Funding

Faculty of Medicine, Khon Kaen University, Thailand.

Declaration of competing interest

The authors declare that there are no conflict of interests of this paper.

Acknowledgements

Piti Ungareevittaya; for the pathological reports including images and their description.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ajoc.2022.101285.

References

1. Coffin CM, Dehner LP, O’Shea PA. Pediatric Soft Tissue Tumors: A Clinical, Pathological, and Therapeutic Approach. Williams & Wilkins; 1997.
2. Saraglia M, Bellan E, Dei Tos AP. The 2020 WHO classification of soft tissue tumours: news and perspectives. Pathologica. November 2020:1–15.
3. Fletcher CD, ed. Diagnostic Histopathology Of Tumors 4. Saunders, Elsevier; 2013.
4. La Quaglia MP, Spizzo SA, Gharavi F, Hajji St, Meyers P, Exelby PR. Liposarcoma in patients younger than or equal to 22 years of age. Cancer. 1993;72(10):3114–3119.
5. Ghadimi MP, Liu P, Peng T, et al. Pleomorphic liposarcoma: clinical observations and molecular variables. Cancer. 2011;117(23):5359–5369.
6. McNab AA, Moseley I. Primary orbital liposarcoma: clinical and computed tomographic features. Br J Ophthalmol. 1990;74:437–439.
7. Cai Y. Primary liposarcoma of the orbit: a clinicopathologic study of seven cases. Ann Diagn Pathol. 2001;5(5):255–266.
8. Monteiro M. Liposarcoma of the orbit presenting as an enlarged medial rectus muscle on CT scan. Br J Ophthalmol. 2002;86:1450.
9. Madge SN, Tumuluri K, Strianese D, et al. Primary orbital liposarcoma. Ophthalmology. 2010;117(3):606–614.
10. Rudzinski E, Mawn L, Kutscher J, Wushensky C, Wills M. Orbital pleomorphic liposarcoma in an eight-year-old boy. Pediatr Dev Pathol. 2011;14(4):339–344.
11. Doyle M, Odashiro AN, Pereira PR, et al. Primary pleomorphic liposarcoma of the orbit: a case report. Orbit. 2012;31(3):168–179.
12. Jang SY, Zhao SY, Kim JH, Kim MJ, Yoon JS, Lee SY. Primary orbital pleomorphic liposarcoma: an aggressive course. Ophthal Plast Reconstr Surg. 2012;28(6):e133–e135.
13. de Bree R, van der Waal I, de Bree E, Leemans CR. Management of adult soft tissue sarcomas of the head and neck. Oral Oncol. 2010;46(11):786–790.
14. de Bree E, Karatzanis A, Hunt JL, et al. Lipomatous tumours of the head and neck: a spectrum of biological behaviour. Eur Arch Oto-Rhino-Laryngol. 2015;272(5):1061–1077.
15. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–581.